Deep brain stimulation of fornix for memory improvement in Alzheimer’s disease: A critical review

Li, Ruofan; Zhang, Chencheng; Rao, Yu; Yuan, Ti‐Fei

doi:10.1016/j.arr.2022.101668

Cited by 21 publications

(18 citation statements)

References 128 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alzheimer's disease (AD) is a neurodegenerative disorder with clinical symptoms of cognitive impairment, memory loss, and learning decline [1]. The pathological characteristics of AD are amyloid-β (Aβ) deposition with neurotoxicity, associated with induced losses of synapses and neurons [2].…”

Section: Introductionmentioning

confidence: 99%

Paeoniflorin Attenuates Lipopolysaccharide-Induced Cognitive Dysfunction by Inhibition of Amyloidogenesis in Mice

Meng

Kim

et al. 2023

IJMS

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a neurodegenerative disease, associated with progressive cognitive impairment and memory loss. In the present study, we examined the protective effects of paeoniflorin against memory loss and cognitive decline in lipopolysaccharide (LPS)-induced mice. Treatment with paeoniflorin alleviated LPS-induced neurobehavioral dysfunction, as confirmed by behavioral tests, including the T-maze test, novel-object recognition test, and Morris water maze test. LPS stimulated the amyloidogenic pathway-related proteins (amyloid precursor protein, APP; β-site APP cleavage enzyme, BACE; presenilin1, PS1; presenilin2, PS2) expression in the brain. However, paeoniflorin decreased APP, BACE, PS1, and PS2 protein levels. Therefore, paeoniflorin reverses LPS-induced cognitive impairment via inhibition of the amyloidogenic pathway in mice, which suggests that paeoniflorin may be useful in the prevention of neuroinflammation related to AD.

show abstract

Section: Introductionmentioning

confidence: 99%

Paeoniflorin Attenuates Lipopolysaccharide-Induced Cognitive Dysfunction by Inhibition of Amyloidogenesis in Mice

Meng

Kim

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Nowadays, due to the predicted increases in the number of Alzheimer's patients, the increase in treatment costs, and the long treatment process, great importance is given to the development of novel drugs in the therapy of AD worldwide [1][2][3][4][5][16][17][18]. In this research, we determined the inhibition activities of some new heterocyclic molecules (6-10) as the target molecules against AChE and BChE (Table 1).…”

Section: The Inhibition Activity Resultsmentioning

confidence: 99%

“…In a literature search, we determined that the target molecules 6, 7, 8 ve 10 except for 9 were synthesized for the first time. On the other hand, the intermediates (1)(2)(3)(4)(5) used in this research to obtain the target compounds were obtained and characterized in one of our previous studies [31]. In that study, the anticholinestrase and antioxidant activities of the intermediates were investigated.…”

Section: Chemistrymentioning

confidence: 99%

“…Alzheimer's disease (AD), which is a fatal neurodegenerative disease, is the most common cause of dementia in the aged population [1][2][3]. It is a nervous system disorder in which damage occurs in neurons in the brain, which manifests itself with progressive loss of cognitive functions such as attention, speech, and decision-making ability, especially memory loss [4,5]. The pathology of progressive and cognitive dysfunction associated with aging in AD remains unclear, and therefore there is still no definitive radical treatment for AD [6].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Some Novel Schiff Base Derivatives as Promising Cholinesterase Inhibitors With Antioxidant Activity Against Alzheimer’s Disease: Synthesis, Characterization and Biological Evaluation

Çınar

Boğa

Topal

et al. 2022

Middle East Journal of Science

View full text Add to dashboard Cite

In this manuscript, five novel Schiff base derivatives containing a pyrazolone ring and a sulfonate moiety (6-10) except for 9 were designed, obtained for the first time and characterized by three spectroscopic techniques. The inhibition performances of these moleucles synthesized in two steps against cholinesterases, namely acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) were evaluated. By DPPH and ABTS assays, antioxidant activities of these molecules were also examined. In AChE assay, compound 6 (95.87±1.59 % inhibition) inhibited this enzyme better than galanthamine (76.98±0.42 % inhibition). In BChE assay, compound 10 with 87.92±1.08% inhibition value in the series indicated the highest activity compared to galanthamine (76.30±0.28 % inhibition). In ABTS radical scavenging assay, compounds 7, 8 and 9 except for 6 and 10 indicated higher antioxidant activities compared to butylated hydroxytoluene (BHT). It is believed that these results may contribute to the design and synthesis of novel antioxidant agents, AChE and BChE inhibitors.

show abstract

“…The accumulation of Aβ plays a central role in the pathogenesis of AD, which contributes to neuronal dysfunction and neurodegeneration. Several mechanisms have been proposed to explain the impact of Aβ on neuronal function, including synaptic dysfunction, oxidative stress and in ammation, mitochondrial dysfunction, neuronal death and tau hyper phosphorylation 25,26 . But, the impact of Aβ aggregation on mRNA m6A modi cation remains illusive.…”

Section: Aβ Plaque Accumulation Is Associated With Mrna M6a Modi Cationmentioning

confidence: 99%

Dynamics of N6-methyladenosine modification during Alzheimer's disease development

Wang

Yang

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

N6-methyladenosine (m6A) modification is a common RNA modification in the central nervous system and has been linked to various neurological disorders, including Alzheimer's disease (AD). However, little is known about the dynamic of mRNA m6A modification and m6A enzymes during the development of AD.Therefore, this study examined the expression profiles of m6A and its enzymes in the development of AD. The results showed that changes in the expression levels of m6A regulatory factors occurred in the early stages of AD, indicating the potential involvement of m6A modification in disease onset. Moreover, the analysis of mRNA m6A expression profiles using m6A-seq revealed significant differences in m6A modification between AD and control brains.The differentially methylated genes were enriched in GO and KEGG terms related to processes such as inflammation response, immune system processes. And the differently expressed genes (DEGs) are negative associated with microglia homeostasis genes and but positive for “disease-associated microglia” (DAM) associated genes, suggesting that dysregulation of mRNA m6A modification may contribute to the development of AD by affecting the function and gene expression of microglia.

show abstract

Deep brain stimulation of fornix for memory improvement in Alzheimer’s disease: A critical review

Cited by 21 publications

References 128 publications

Paeoniflorin Attenuates Lipopolysaccharide-Induced Cognitive Dysfunction by Inhibition of Amyloidogenesis in Mice

Paeoniflorin Attenuates Lipopolysaccharide-Induced Cognitive Dysfunction by Inhibition of Amyloidogenesis in Mice

Some Novel Schiff Base Derivatives as Promising Cholinesterase Inhibitors With Antioxidant Activity Against Alzheimer’s Disease: Synthesis, Characterization and Biological Evaluation

Dynamics of N6-methyladenosine modification during Alzheimer's disease development

Contact Info

Product

Resources

About